RedHill Biopharma Ltd. (NASDAQ: RDHL) Receives Consensus “Buy” Rating from Analysts

The shares of RedHill Biopharma Ltd. (NASDAQ: RDHL – Get Rating) received a consensus rating of “Buy” from the seven rating companies that currently cover the company, MarketBeat Ratings reports. Two investment analysts rated the stock with a hold recommendation and five gave the company a buy recommendation. The 12-month average price target among analysts who have updated their coverage of the stock over the past year is $17.25.

RDHL has been the subject of several recent research reports. launched coverage on RedHill Biopharma stocks in a research note on Thursday, March 31. They issued a “holding” rating on the stock. Zacks Investment Research moved shares of RedHill Biopharma from a “buy” rating to a “hold” rating in a Wednesday, May 4, research note.

Institutional investors have recently increased or reduced their stake in the company. Advisor Group Holdings Inc. increased its position in shares of RedHill Biopharma by 288.7% in the third quarter. Advisor Group Holdings Inc. now owns 24,101 shares of the biotech company worth $110,000 after acquiring 17,901 additional shares in the last quarter. CLARET ASSET MANAGEMENT Corp increased its position in RedHill Biopharma by 14.1% during the third quarter. CLARET ASSET MANAGEMENT Corp now owns 62,730 shares of the biotech company valued at $287,000 after buying 7,758 more shares last quarter. Ancora Advisors LLC acquired a new position in RedHill Biopharma during the third quarter, valued at approximately $172,000. BlackRock Inc. increased its position in RedHill Biopharma by 8.2% during the third quarter. BlackRock Inc. now owns 312,139 shares of the biotech company valued at $1,430,000 after buying an additional 23,776 shares last quarter. Finally, GSA Capital Partners LLP increased its position in RedHill Biopharma by 28.1% during the third quarter. GSA Capital Partners LLP now owns 104,754 shares of the biotech company valued at $480,000 after buying an additional 22,976 shares last quarter. 11.08% of the shares are currently held by institutional investors and hedge funds.

RDHL stock opened at $0.94 on Friday. RedHill Biopharma has a 52 week minimum of $0.90 and a 52 week maximum of $11.18. The company has a market capitalization of $49.52 million, a price-earnings ratio of -0.45 and a beta of 1.90. The company’s 50-day moving average is $2.07 and its two-hundred-day moving average is $2.72. The company has a current ratio of 1.09, a quick ratio of 0.91 and a debt ratio of 9.42.

RedHill Biopharma (NASDAQ:RDHL – Get Rating) last reported quarterly earnings data on Thursday, March 17. The biotech company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.10). The company posted revenue of $22.07 million in the quarter, compared to analyst estimates of $22.99 million. RedHill Biopharma had a negative return on equity of 379.42% and a negative net margin of 113.98%. During the same period of the previous year, the company achieved EPS of ($0.70). On average, equity research analysts expect RedHill Biopharma to post -0.96 earnings per share for the current year.

About RedHill Biopharma (Get an assessment)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, is primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of traveller’s diarrhea in adults.

Recommended Stories

Analyst Recommendations for RedHill Biopharma (NASDAQ: RDHL)

Get news and reviews for RedHill Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for RedHill Biopharma and related companies with’s FREE daily newsletter.